FILTER

FILTERED INTERVIEW RESULTS

Mining
Peru

Guillaume Légaré

HEAD – SOUTH AMERICA, TORONTO STOCK EXCHANGE AND TSX VENTURE EXCHANGE
TSX and TSXV enjoyed an exciting year in 2020 with relation to Latin America, where C$2.9 billion equity capital was raised by companies that have mining projects in the region.
Mining
Peru

Wilson Miranda

GENERAL MANAGER, CONFIPETROL ANDINA
Confipetrol Andina comments on opportunities for 2021 in Peru’s mining sector.
Mining
Peru

Michael W. Scherb

FOUNDER & CEO, APPIAN CAPITAL ADVISORY LLP
Appian Capital Advisory has raised US$775 million for its second fund, Appian Natural Resources Fund II.
Mining
Peru

Adolfo Vera

PRESIDENT & CEO, SOUTHERN PEAKS MINING
Peru Mining 2021 Pre-Release Edition
Southern Peaks Mining is IPO ready and attempting significant expansion.
Mining
Peru

David Kelley

PRESIDENT & CEO, CHAKANA COPPER
Chakana Copper describes plans for its Soledad property in Peru.
Mining
Peru

Jorge León Benavides

PRESIDENT, CANADA PERU CHAMBER OF COMMERCE (CCCP)
The Canada Peru Chamber of Commerce continues looking at means of attracting further investments into Peru’s mining industry.
Mining
Peru

Víctor Gobitz

PRESIDENT, PERUVIAN INSTITUTE OF MINING ENGINEERS (IIMP)
The Peruvian Institute of Mining Engineers sets forth the challenges for the country’s mining industry in 2021.
Mining
Peru

Jay Chmelauskas

PRESIDENT & CEO, CAMINO CORPORATION
Camino Corp. explains its restart of the Los Chapitos copper project.
Mining
Peru

Carlos Leigh

CEO – LATIN AMERICA, DSI UNDERGROUND
DSI Underground discusses the recovery in mining activity in Latin America following lockdowns.
Mining
Peru

Sandro Tavonatti

CEO, INGENIERÍA Y CONSTRUCCIÓN SIGDO KOPPERS
Ingeniería y Construcción Sigdo Koppers in Peru comments on its ongoing projects in the mining sector in Peru.

MACIG

SPANISH

SUBSCRIBE TO OUR NEWSLETTER

RECENT PUBLICATIONS

United States Life Sciences 2025 - Digital Interactive

Resilience amid uncertainty. These words encapsulate the US life sciences sector as it navigates 2025. While the industry has largely rebounded from the recent biotech bear market, with clinical trial starts and funding showing signs of rebound, headwinds remain.
MORE PREVIOUSLY PUBLISHED

PARTNER EVENTS

SEE ALL